Intelligent Bio Solutions Successfully Completes Recruitment and Begins Subject Screening for FDA 510(k) Pharmacokinetic (PK) Study
- NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful recruitment and commencement of screening for subjects in its pharmacokinetic (PK) study, a critical component of the Company's FDA 510(k) regulatory pathway for clearance.
- 05/29/2024
|
Intelligent Bio Solutions Unveils Key Performance Indicator Growth in the United Kingdom as Drug Screening Industry Combats Drug Test Cheating and Searches for Simpler, Faster, Non-Invasive and More Cost-Effective Solutions
- NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today unveiled key performance indicators from its United Kingdom operations. These indicators have contributed to the Company's growth as the drug screening industry continues to combat drug test cheating and searches for simpler, faster, non-invasive, and more cost-effective solutions.
- 05/23/2024
|
CCC Intelligent Solutions Holdings Inc. (NYSE:CCCS) Shares Acquired by Amalgamated Bank
- Amalgamated Bank increased its stake in shares of CCC Intelligent Solutions Holdings Inc. (NYSE:CCCS – Free Report) by 34.7% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 40,799 shares of the company’s stock after acquiring an additional 10,513 shares during the period. Amalgamated Bank’s holdings in CCC Intelligent Solutions were worth $465,000 at the end of the most recent reporting period. A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Park Place Capital Corp boosted its stake in shares of CCC Intelligent Solutions by 65.9% in the fourth quarter. Park Place Capital Corp now owns 4,175 shares of the company’s stock valued at $48,000 after purchasing an additional 1,659 shares during the period. Covestor Ltd boosted its position in CCC Intelligent Solutions by 781.7% in the 3rd quarter. Covestor Ltd now owns 6,895 shares of the company’s stock valued at $92,000 after buying an additional 6,113 shares during the last quarter. Parkside Financial Bank & Trust acquired a new stake in shares of CCC Intelligent Solutions during the fourth quarter valued at about $99,000. Envestnet Portfolio Solutions Inc. purchased a new stake in shares of CCC Intelligent Solutions during the third quarter worth about $143,000. Finally, Cerity Partners LLC purchased a new position in CCC Intelligent Solutions in the fourth quarter valued at about $149,000. Hedge funds and other institutional investors own 95.79% of the company’s stock. Insiders Place Their Bets In other news, CAO Rodney Christo sold 30,000 shares of the business’s stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $12.50, for a total transaction of $375,000.00. Following the completion of the transaction, the chief accounting officer now directly owns 14,154 shares in the company, valued at $176,925. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other CCC Intelligent Solutions news, Director Lauren Young sold 41,165,139 shares of the firm’s stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $11.33, for a total transaction of $466,401,024.87. Following the transaction, the director now owns 5,164,022 shares of the company’s stock, valued at approximately $58,508,369.26. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CAO Rodney Christo sold 30,000 shares of the company’s stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $12.50, for a total transaction of $375,000.00. Following the completion of the sale, the chief accounting officer now directly owns 14,154 shares of the company’s stock, valued at $176,925. The disclosure for this sale can be found here. In the last 90 days, insiders sold 59,706,755 shares of company stock worth $681,785,331. Insiders own 6.67% of the company’s stock. Wall Street Analysts Forecast Growth CCCS has been the subject of several research analyst reports. Piper Sandler increased their target price on CCC Intelligent Solutions from $11.00 to $13.00 and gave the company a “neutral” rating in a research note on Friday, March 1st. Barrington Research reiterated an “outperform” rating and set a $14.00 price objective on shares of CCC Intelligent Solutions in a research note on Wednesday, May 1st. Barclays upped their target price on shares of CCC Intelligent Solutions from $13.00 to $14.00 and gave the company an “equal weight” rating in a research note on Thursday, February 29th. Citigroup reiterated a “buy” rating and issued a $13.00 price target on shares of CCC Intelligent Solutions in a research note on Thursday, February 8th. Finally, Evercore ISI increased their target price on CCC Intelligent Solutions from $13.00 to $15.00 and gave the stock an “outperform” rating in a report on Wednesday, March 13th. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, CCC Intelligent Solutions currently has an average rating of “Moderate Buy” and an average price target of $13.63. Read Our Latest Stock Analysis on CCCS CCC Intelligent Solutions Trading Up 2.1 % Shares of NYSE CCCS opened at $11.21 on Monday. The company has a market cap of $6.89 billion, a price-to-earnings ratio of -53.38 and a beta of 0.63. The stock’s 50 day simple moving average is $11.51 and its 200 day simple moving average is $11.39. The company has a current ratio of 2.53, a quick ratio of 2.53 and a debt-to-equity ratio of 0.43. CCC Intelligent Solutions Holdings Inc. has a 12-month low of $9.32 and a 12-month high of $13.41. CCC Intelligent Solutions (NYSE:CCCS – Get Free Report) last announced its quarterly earnings results on Wednesday, February 28th. The company reported $0.04 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.05 by ($0.01). CCC Intelligent Solutions had a negative net margin of 10.85% and a positive return on equity of 4.52%. The firm had revenue of $228.60 million for the quarter, compared to analyst estimates of $222.80 million. Equities research analysts expect that CCC Intelligent Solutions Holdings Inc. will post 0.16 EPS for the current year. CCC Intelligent Solutions Profile (Free Report) CCC Intelligent Solutions Holdings Inc, operates as a software as a service company for the property and casualty insurance economy in the United States and China. The company's cloud-based software as a service platform connects trading partners, facilitates commerce, and supports mission-critical, artificial intelligence enabled digital workflow across the insurance economy, including insurers, repairers, automakers, parts suppliers, lenders and more. See Also Five stocks we like better than CCC Intelligent Solutions 3 Grocery Stocks That Can Help Take a Bite Out of Inflation MarketBeat Week in Review – 5/13 – 5/17 What is the Nikkei 225 index? Take-Two Interactive Software Offers 2nd Chance for Investors Why Invest in High-Yield Dividend Stocks? Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook
- 05/20/2024
|
Innovative Fingerprint Drug Screening Solution Showcased at the UK's Premier Health and Safety Event
- NEW YORK, May 17, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful exhibition of its Intelligent Fingerprinting Drug Screening Solution at The Health & Safety Event 2024, the United Kingdom's largest annual technology showcase exhibiting products and services that strengthen and support workplace safety standards. According to the event website, this year's event welcomed over 250+ industry-leading exhibitors and over 11,500 attendees, including visitors from major brands such as Amazon, PepsiCo, Rolls Royce, Jaguar Land Rover, and Harvey Nichols.
- 05/17/2024
|
Intelligent Bio Solutions Inc. Reports Fiscal 2024 Third Quarter and Nine-Month Financial Results and Operational Highlights
- Year-over-year revenue increased 80% for the fiscal third quarter and 193% for the nine months ended March 31, 2024
- 05/08/2024
|
Intelligent Bio Solutions Inc. Announces Preliminary Unaudited Fiscal Third Quarter and Nine-Month Revenue Results
- Year-over-year unaudited revenue increased 80% for the fiscal third quarter and 193% for the nine months ended March 31, 2024, with highest quarterly cartridge sales since 2022 Intelligent Fingerprinting acquisition Year-over-year unaudited revenue increased 80% for the fiscal third quarter and 193% for the nine months ended March 31, 2024, with highest quarterly cartridge sales since 2022 Intelligent Fingerprinting acquisition
- 04/18/2024
|
Intelligent Bio Solutions Subsidiary Broadens Intellectual Property Portfolio with Grant of New European Patent with Unitary Effect for Innovative Intelligent Fingerprinting DSR-Plus Cartridge Reader
- NEW YORK, April 11, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (“INBS” or the “Company”) (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the broadening of the intellectual property portfolio of its wholly owned subsidiary, Intelligent Fingerprinting Limited, with the grant of a new European patent with unitary effect for its ground-breaking DSR-Plus Cartridge Reader. This latest achievement follows the successful protection of the same technology in the United Kingdom and marks another significant milestone in the Company's expansion and protection of its intellectual property.
- 04/11/2024
|
Intelligent Bio Solutions to Present at the LD Micro Invitational XIV Investor Conference on April 9 in NYC
- NEW YORK, March 26, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. ("INBS" or the "Company") (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that President and CEO, Harry Simeonidis, and CFO, Spiro Sakiris, are scheduled to present at the LD Micro Invitational XIV Investor Conference to be held on April 8-9, 2024 in New York City.
- 03/26/2024
|
Intelligent Bio Solutions Announces Closing of $10.1 Million Private Placement Priced At-the-Market Under Nasdaq Rules
- NEW YORK, March 12, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. ("INBS" or the "Company") (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the closing of its previously announced private placement priced at-the-market under Nasdaq rules of 2,223,333 shares of common stock (or pre-funded warrants in lieu thereof), Series H-1 warrants to purchase up to an aggregate of 2,223,333 shares of common stock and Series H-2 warrants to purchase up to an aggregate of 2,223,333 shares of common stock, at a combined purchase price of $4.55 per share of common stock (or pre-funded warrant) and associated Series H-1 warrants and Series H-2 warrants. The gross proceeds to INBS from the private placement were approximately $10.1 million, before deducting placement agent fees and other offering expenses payable by the Company. The Series H-1 warrants and Series H-2 warrants have an exercise price of $4.55 per share of common stock and are exercisable immediately upon issuance. The Series H-1 warrants have a term of eighteen months following the date a registration statement registering all warrant shares underlying the Series H-1 warrants is declared effective by the United States Securities and Exchange Commission (“SEC”). The Series H-2 warrants have a term of exercise equal to five years, which will be reduced to 20 calendar days following any date the Company makes a public announcement of 510k clearance by the U.S. Food and Drug Administration (FDA) of the Company's Intelligent Fingerprinting Drug Screening System.
- 03/12/2024
|
Intelligent Bio Solutions Announces $10.1 Million Private Placement Priced At-the-Market Under Nasdaq Rules
- NEW YORK, March 11, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. ("INBS" or the "Company") (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that on March 8, 2024, it entered into securities purchase agreements with several healthcare-focused institutional and accredited investors to issue, in a private placement priced at-the-market under Nasdaq rules, 2,223,333 shares of common stock (or pre-funded warrants in lieu thereof), Series H-1 warrants to purchase up to an aggregate of 2,223,333 shares of common stock and Series H-2 warrants to purchase up to an aggregate of 2,223,333 shares of common stock, at a combined purchase price of $4.55 per share of common stock (or pre-funded warrant) and associated Series H-1 warrants and Series H-2 warrants, for expected gross proceeds to INBS of approximately $10.1 million, before deducting placement agent fees and other offering expenses payable by the Company. The Series H-1 warrants and Series H-2 warrants will have an exercise price of $4.55 per share of common stock and will be exercisable immediately upon issuance. The Series H-1 warrants will have a term of eighteen months following the date a registration statement registering all warrant shares underlying the Series H-1 warrants is declared effective by the United States Securities and Exchange Commission (“SEC”). The Series H-2 warrants will have a term of exercise equal to five years, which will be reduced to 20 calendar days following any date the Company makes a public announcement of 510k clearance by the U.S. Food and Drug Administration (FDA) of the Company's Intelligent Fingerprinting Drug Screening System.
- 03/11/2024
|
Intelligent Bio Solutions Inc. to Present at the Emerging Growth Conference on March 6, 2024
- NEW YORK, March 01, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that it will present at the Emerging Growth Conference on March 6, 2024. INBS will provide an update on the Company's growth and financial performance in 2023, among other topics.
- 03/01/2024
|
Intelligent Bio Solutions Partners with Cliantha Research to Conduct Clinical Study as Part of FDA 510(k) Pathway
- NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. ("INBS" or the "Company") (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its partnership with Cliantha Research, a full-service Clinical Research Organization (CRO), to perform a pharmacokinetic (PK) study forming part of the Company's FDA 510(k) clinical study plan.
- 02/28/2024
|
Intelligent Bio Solutions Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement and Confirms Compliance with Minimum Stockholders' Equity Requirement
- NEW YORK, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. ("INBS" or the "Company") (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that on February 13, 2024, it received written notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires that the Company's common stock maintain a minimum bid price of $1.00 per share (the “Minimum Bid Price Requirement”).
- 02/16/2024
|
Why Is Intelligent Bio Solutions (INBS) Stock Down 24% Today?
- Intelligent Bio Solutions (NASDAQ: INBS ) stock is falling on Monday following the release of the medical technology company's earnings report for its fiscal second quarter of 2024. The Intelligent Bio Solutions earnings release includes adjusted earnings per share of -$2.07.
- 02/12/2024
|
Intelligent Bio Solutions Inc. Reports Fiscal Second Quarter and Six-Month Financial Results and Operational Highlights
- - Year-over-year revenue increased 114% for the fiscal second quarter and 337% for the six-months ending December 31, 2023 - - Expanded into New Zealand market and increased market share in existing regions -
- 02/09/2024
|
Intelligent Bio Solutions Inc. Announces Exercise of Previously Issued Warrants for $1.77 Million in Gross Proceeds
- NEW YORK, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced an agreement between the Company and several current warrant holders to exercise certain existing Series E Warrants (the “Existing Warrants”) to purchase up to an aggregate of 606,064 shares of common stock that were issued on October 4, 2023, in an underwritten public offering. The Existing Warrants have an exercise price of $2.9232 per share.
- 02/05/2024
|
Intelligent Bio Solutions Inc. Announces Preliminary Unaudited Fiscal Second Quarter and Six-Month Revenue Results
- - Year-over-year unaudited revenue increased 114% for the fiscal second quarter and 337% for the six months ended December 31, 2023 - - Year-over-year unaudited revenue increased 114% for the fiscal second quarter and 337% for the six months ended December 31, 2023 -
- 02/02/2024
|
Fingerprint Drug Test Delivers Quantifiable Benefits for Customers as Adoption in Workplaces Accelerates
- Customers identify in-house control, project flexibility, productivity, and cost reductions as key business benefits of fingerprint sweat-based drug testing
- 01/30/2024
|
Leading UK Timber Processor and Packaging Manufacturer, James Jones & Sons Ltd., Adopts Intelligent Bio Solutions' Fingerprint Drug Screening System Across its 25 Sites and 1,300 Employees
- Intelligent Fingerprinting to be used for in-house drug testing, enabling full testing control to support new James Jones drug and alcohol testing policy
- 01/29/2024
|
Intelligent Bio Solutions Inc. Announces Reverse Stock Split
- NEW YORK, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“Intelligent Bio Solutions” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that it will effect a 1-for-12 reverse split of its common stock, that will become effective at 5:00 pm (Eastern Time) on January 26, 2024. Trading of the Company's common stock on The Nasdaq Capital Market (“Nasdaq”) will continue, on a split-adjusted basis, with the opening of the markets on January 29, 2024, under the trading symbol “INBS” and new CUSIP number 36151G600.
- 01/25/2024
|
DGP Plc Takes Drug Testing In-house with Fingerprint Sweat-based Testing
- Construction logistics, security, and support specialist selects Intelligent Fingerprinting Drug Screening System to simplify and speed up workplace drug testing for its 450 employees and contractors
- 01/22/2024
|
UK's largest independent chemical manufacturer takes drug testing in-house with Intelligent Fingerprinting Drug Screening System
- NEW YORK, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that Robinson Brothers, one of the UK's largest independent chemical manufacturers, is now using its revolutionary portable Intelligent Fingerprinting Drug Screening System to support its drug and alcohol testing policy.
- 01/18/2024
|
Intelligent Bio Solutions Receives NATA Accreditation for its Revolutionary Fingerprint Sweat Drug Screening System
- NEW YORK, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (“INBS” or the “Company”) (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that it has received National Association of Testing Authorities (NATA) accreditation for its Intelligent Fingerprinting Drug Screening Solution.
- 12/19/2023
|
Leading Pan-European Ferry and Logistics Company, P&O Ferries, Adopts Fingerprint Drug Screening Solution for On-Board, Random Testing of Seafaring Staff
- Intelligent Fingerprinting Drug Screening System is expected to reduce P&O Ferries' overall drug testing costs by 90%
- 12/05/2023
|
Intelligent Bio Solutions Inc. to Present at the Emerging Growth Conference on December 7, 2023
- NEW YORK, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that it will present at the Emerging Growth Conference on December 7, 2023. The Company will provide insight into the Company's unique proprietary Intelligent Fingerprinting Drug Screening System, among other topics.
- 11/29/2023
|
Why Is Intelligent Bio Solutions (INBS) Stock Down 48% Today?
- Intelligent Bio Solutions (NASDAQ: INBS ) stock is taking a beating on Wednesday after the company announced a proposed public stock offering. The company announced that offering yesterday, and then released details of the offering early this morning.
- 03/08/2023
|
7 Penny Stocks To Watch With Big News In February; Time To Buy?
- Penny stocks to watch with news this month. The post 7 Penny Stocks To Watch With Big News In February; Time To Buy?
- 02/07/2023
|
7 Top Penny Stocks To Watch With Big News This Week
- Penny Stocks With News Light Up The Scanners This Week This week
- 01/31/2023
|
The Benefits of Short Term Trading Penny Stocks
- Should you use a short term penny stocks trading strategy? The post The Benefits of Short Term Trading Penny Stocks appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 01/25/2023
|
These Tips Could Make You Money With Penny Stocks
- Use these tips to help make money with penny stocks in 2023 The post These Tips Could Make You Money With Penny Stocks appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 01/24/2023
|
Why Is Intelligent Bio Solutions (INBS) Stock Up 363% Today?
- Intelligent Bio Solutions (NASDAQ: INBS ) stock is rocketing higher on Monday thanks to a new milestone for the biosensor company. As detailed in a press release, the development of Intelligent Bio Solutions' biosensor platform is going well.
- 01/23/2023
|
Best Penny Stocks To Buy? 5 To Watch After Big News This Week
- Penny stocks to watch with news that are turning heads in the stock market this week. The post Best Penny Stocks To Buy?
- 01/23/2023
|
Intelligent Bio Solutions Inc. (INBS) Q1 2023 Earnings Call Transcript
- Intelligent Bio Solutions Inc. (NASDAQ:INBS ) Q1 2023 Earnings Conference Call November 9, 2022 4:30 PM ET Company Participants Harry Simeonidis - Chairman and CEO Spiro Sakiris - Chief Financial Officer Philip Hand - Executive Chairman, Intelligent Fingerprinting Limited Conference Call Participants John Vandermosten - Zacks Operator Greetings. And welcome to the Intelligent Bio Solutions Inc. First Quarter 2023 Earnings Conference Call.
- 11/11/2022
|
